Abstract
Type 2 diabetes mellitus is one of the most important independent risk factors for the development, progression and mortality from cardiovascular diseases (CVD). The world communities are faced with the question of developing the optimal management tactics for such comorbidity patients. Thus, the prescribed drug should not only have an adequate hypoglycemic effect, but also have a number of cardioprotective properties, be safe in patients with CVD, and possibly even improve the prognosis and reduce mortality rates. This review is devoted to a representative of the biguanide class - metformin, which is one of the earliest and most effective antihyperglycemic drugs, both as monotherapy and in combination with other antihyperglycemic drugs and insulin; while the evidence base for its cardiovascular profile is only gaining momentum. Thus, the purpose of this review is to highlight the cardiovascular effects of metformin in the context of recent research.
Highlights
Cardiovascular Effects of Metformin Kurmanbekova B.T.*, Noruizbaeva A.M
National Center of cardiology and internal medicine named after academician M.Mirrakhimov
This review is devoted to a representative of the biguanide class - metformin, which is one of the earliest and most effective antihyperglycemic drugs, both as monotherapy and in combination with other antihyperglycemic drugs and insulin; while the evidence base for its cardiovascular profile is only gaining momentum
Summary
Сахарный диабет 2 типа является одним из важнейших независимых факторов риска развития, прогрессирования и смертности от сердечно-сосудистых заболеваний (ССЗ). Назначаемый препарат должен оказывать не только адекватный гипогликемический эффект, но и обладать рядом кардиопротективных свойств, быть безопасным у больных ССЗ и, возможно, улучшать прогноз и снижать показатели смертности. Cardiovascular Effects of Metformin Kurmanbekova B.T.*, Noruizbaeva A.M. National Center of cardiology and internal medicine named after academician M.Mirrakhimov. На сегодняшний день возможные механизмы, через которые осуществляются благоприятные кардиоваскулярные эффекты метформина, в большей степени связаны с сосудами, включая влияние непосредственно на клетки эндотелия и гладкомышечные клетки (ГМК), липиды и хроническое системное воспаление [4]. Rational Pharmacotherapy in Cardiology 2022;18(1) / Рациональная Фармакотерапия в Кардиологии 2022;18(1). Cardiovascular Effects of Metformin Кардиоваскулярные эффекты метформина сосудистой системе. Данный эффект связан отнюдь не с гипогликемическими свойствами препарата, а со способностью снижать уровень тканевого ингибитора плазминогена-1 (эндотелиального фактора фибринолиза) [9]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
